A5044862325- Cancer Genomics and Diagnostics
- Molecular Biology Techniques and Applications
- Advanced Breast Cancer Therapies
- Single-cell and spatial transcriptomics
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Endometriosis Research and Treatment
- Gene expression and cancer classification
- Epigenetics and DNA Methylation
- Reproductive System and Pregnancy
- Global Cancer Incidence and Screening
- Multiple and Secondary Primary Cancers
- Gut microbiota and health
- Environmental DNA in Biodiversity Studies
- Cancer-related molecular mechanisms research
- Cancer Risks and Factors
- Endometrial and Cervical Cancer Treatments
- Cancer Cells and Metastasis
Instituto de Investigación Biomédica de Málaga
2020-2024
Hospital Clínico Universitario Virgen de la Victoria
2023-2024
Universidad de Málaga
2023
PURPOSE Data from population-based studies have shown an increased incidence of certain types neoplasms in patients younger than 50 years (early-onset cancer [EOC]); however, little information is derived other real-world data sources. In a nonpopulation registry, we analyzed changes the several successive generations. METHODS This cross-sectional study included all with diagnosis registered one university hospital Málaga, Spain, between 1998 and 2021, 18 were analyzed. For each neoplasm,...
Analysis of circulating tumor DNA (ctDNA) is increasingly used for clinical decision-making in oncology. However, ctDNA could represent ≤ 0.1 % cell-free early-stage tumors and its detection requires high-sensitive techniques such as digital PCR (dPCR).
Early breast cancer patients often experience relapse due to residual disease after treatment. Liquid biopsy is a methodology capable of detecting tumor components in blood, but low concentrations at early stages pose challenges. To detect them, next-generation sequencing has promise entails complex processes. Exploring larger blood volumes could overcome detection limitations. Herein, total 282 high-volume plasma and blood-cell samples were collected for dual ctDNA/CTCs using single...
Abstract Breast cancer (BC) is the most frequent neoplasia affecting women worldwide normally detected at early stages. In this regard, diagnosis drastically decreases mortality, however, around 20% of these patients will later relapse. This mainly caused by undetectable molecular residual disease (MRD) not eliminated standard primary treatments. Therefore, it crucial to detect after-treatment MRD stratify their risk Liquid biopsies have emerged as non-invasive method obtain information...
e13040 Background: The treatment of luminal MBC has undergone a substantial change with the use cyclin dependent kinase 4/6 inhibitors (CDKIs). Nevertheless, there is not clearly defined subgroup patients who do initially respond to CDKIs and show EP. Methods: ER+/HER2- have received at least one line were eligible. event interest was disease progression within 6 months first according type therapy administered. treatments categorized in chemotherapy (CT), hormonal (HT), CT plus maintenance...
e13035 Background: CDK 4/6 inhibitors plus hormone therapy(HT) has been approved by FDA and EMA for the treatment of receptor positive HER2 negative advanced breast cancer (HR+/HER2-BC) with improvement in PFS consistently demonstrated several clinical trials. Benefit OS also Monaleesa3 Monarch2 To date we don`t have real-world data no single biomarker validated to identify subgroups that would benefit most from this new drugs. Methods: This is a multicenter, real life, observational study....